Medical University of South Carolina partners with Shoreline Behavioral Health Services to introduce clinical trials.
Clinical Trial 1: Clinical Trial Network’s (CTN) Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Purpose of the Research Study
The purpose of this research study is to test approaches to improve outcomes for patients who want to discontinue their medication for opioid use disorder after a period of remaining stable on medication.
For more information contact the Study Coordinator at 843-698-2741
Clinical Trial 2: UH3 – Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
Background
Researchers at Shoreline Behavioral Health Services are conducting a research study to test a new combination of medicines for outpatient treatment of opioid withdrawal.
Findings from this clinical research study will determine whether new approaches to treating withdrawal will improve our ability to use extended-release naltrexone (Vivitrol) as relapse prevention medication.
Potential participants will be screened and, if eligible, will be randomized to receive either Lofexidine + Pregabalin OR Lofexidine + Placebo. There will be daily check-ins during the 8-day outpatient opioid detoxification to determine withdrawal symptoms.
For more information contact the Study Coordinator at 843-698-2741
Clinical Trial 3: Substance Use Trial of E-Cigarettes or Pharmacotherapy for Smoking (STEPS Study)
Purpose of the Research Study
Individuals with substance use disorders (SUD) are more likely to use combustible tobacco (cigarettes) and less likely to quit smoking than individuals in the general population, but few efficacious treatment options exist for this population and many SUD programs do not offer tobacco treatment. Electronic nicotine delivery systems (ENDS; e-cigarettes) are non-combusted tobacco products that have been shown to deliver lower levels of toxicants than traditional cigarettes, and represent an appealing, pragmatic and potentially viable alternative to evaluate among an SUD treatment population. The proposed Hybrid Type 1 effectiveness-implementation trial will evaluate the impact of a tobacco harm reduction strategy, namely switching to ENDS, compared to quitting with traditional pharmacotherapy on cigarette smoking, SUD treatment outcomes and engagement and will evaluate implementation outcomes to support the eventual dissemination of this harm reduction strategy within SUD treatment settings.
For more information contact the Study Coordinator at 843-698-2741
